Core Viewpoint - Contineum Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of its Class A common stock at $12.25 per share, indicating a strategic move to raise capital for its clinical-stage biopharmaceutical initiatives [1] Company Summary - The company is focused on developing differentiated therapies targeting neuroscience, inflammation, and immunology (NI&I) indications, highlighting its commitment to advancing treatment options in these critical areas [1] - The public offering consists of 7,346,938 shares, which reflects an increase in the size of the offering, suggesting strong investor interest and confidence in the company's future prospects [1] - Contineum has provided underwriters with a 30-day option, which may allow for additional shares to be sold, further indicating the company's proactive approach to capitalizing on market conditions [1]

Core Viewpoint - The Russell 2000 index is positioned to potentially be the second-best-performing index in the U.S. stock exchanges as 2025 approaches, driven by a significant shift towards small-cap stocks due to the Federal Reserve's easing cycle [1]. Interest Rate Impact - The Federal Reserve has reduced the benchmark federal funds rate by 25 basis points, bringing it to a range of 3.5-3.75%, down from a high of 5.25-5.5% in 2023 during a tightening cycle aimed at controlling post-pandemic inflation [2]. Small Business Financing - Lower interest rates are favorable for small businesses, particularly as the period from mid-December to early March is historically strong for the Russell 2000 due to tax-loss harvesting and increased investor risk appetite at the start of the new year [3]. Top Performers in Russell 2000 - **Celcuity (CELC)**: - Stock Price: $100 - YTD Return: +695% - Market Cap: $4.71 billion - The company focuses on cellular analysis and precision oncology, experiencing significant stock price increases due to breakthrough clinical trials [5][6]. - **Better Home & Finance (BETR)**: - Stock Price: $48 - YTD Return: +442% - Market Cap: $794.72 million - Operates as an AI-powered mortgage lender and fintech company, with projected annual sales growth of over 50% this year and 67% next year [9][12]. - **Cogent Biosciences (COGT)**: - Stock Price: $40 - YTD Return: +413% - Market Cap: $5.58 billion - Focused on precision therapies for genetically defined diseases, with strong clinical progress on its lead drug, bezuclastinib [13][14]. Earnings Projections - Celcuity is expected to report a loss of -$3.86 per share in FY25 and -$4.05 in FY26, despite positive EPS revisions [8]. - Better Home's EPS revisions for FY25 and FY26 have slightly decreased, indicating potential short-term momentum loss [12]. - Cogent is projected to have a narrower adjusted loss of -$1.77 per share in FY26, with modestly higher EPS revisions in the last 60 days [14]. Investment Considerations - The strong performance of the Russell 2000 suggests that these top-performing stocks may be worth monitoring, although better buying opportunities may arise in the future [16].

Company Performance - Rezolute, Inc. (NASDAQ:RZLT) experienced a dramatic stock price drop to $1.32, reflecting an 87.93% decrease due to a failed Phase 3 study and subsequent investigation by Holzer & Holzer, LLC [1][6] - Oriental Culture Holding Ltd. (NASDAQ:OCG) saw its stock price decline to $1.57, an 81.95% decrease, potentially influenced by its unaudited financial results for the first half of 2025 [2][6] - C3is Inc. (NASDAQ:CISS) reported a stock price drop to $0.34, a 79.82% decrease, amid broader industry challenges and its financial results for the third quarter [3][6] - GRI Bio, Inc. (NASDAQ:GRI) faced a 54.70% decline in stock price to $0.54, linked to its public offering announcement of $8 million [4][6] - Thunder Power Holdings, Inc. (OTCQB:AIEV) saw its stock price decrease to $0.14, a 49.58% drop, as it reported third-quarter results and plans for asset integration and renewable energy expansion [5] Market Trends - The significant price movements across various sectors, including biotechnology, e-commerce, marine shipping, and electric vehicle manufacturing, indicate heightened volatility in the market [5] - Factors contributing to these declines include company-specific news such as earnings reports and strategic decisions, as well as broader market trends and economic indicators [5]

Core Insights - Rezolute, Inc. faced a significant setback with its Phase 3 sunRIZE study for treating congenital hyperinsulinism, leading to a dramatic decline in stock performance [1][5] Group 1: Study Results - The sunRIZE study did not meet its primary endpoint, with the highest dose of ersodetug achieving only a 45% reduction in hypoglycemia events, which was not statistically significant compared to the placebo group's 40% reduction [2][5] - The trial also failed to meet its key secondary endpoint, showing a 25% reduction in average daily percent time in hypoglycemia for the top dose, while the placebo group experienced a 5% increase [3][5] - Despite these failures, the company reported that target drug concentrations were achieved across all age groups, and safety observations were generally favorable, although two participants experienced serious hypersensitivity reactions [3] Group 2: Stock Performance - Following the disappointing trial results, Wedbush set a price target of $1 for RZLT, indicating a potential decrease of approximately -19.68% from its trading price of $1.245 [2][5] - The stock has seen a significant decline of 88.21% from its previous value, currently priced at $1.29, with fluctuations between a low of $1.07 and a high of $1.41 [4][5] - Over the past year, the stock reached a high of $11.46 and a low of $1.07, with a current market capitalization of approximately $119.62 million and a trading volume of 91.55 million shares [4]

®Combination of Keytruda and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patients Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose Results Support Advancement of the Program into Phase 2 Development In Cohort Ic, a key objective was to assess whether administration of the investigational vaccine in combination with pembrolizumab could create intolerable side ...

Core Insights - Applied Therapeutics has entered into a definitive agreement for Cycle Group Holdings Limited to acquire the company, focusing on advancing its lead drug candidate, govorestat, for rare CNS metabolic diseases [1][3][6] Company Overview - Applied Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates targeting rare diseases, with its lead candidate being govorestat, an Aldose Reductase Inhibitor for CNS rare metabolic diseases [2][10] Acquisition Details - Cycle will initiate a tender offer to acquire all outstanding shares of Applied common stock at a price of $0.088 per share in cash, along with a non-transferrable contingent value right (CVR) for potential additional payments [3][4] - The CVR includes payments based on FDA approvals and sales milestones, with potential cash payments of up to $0.10 for FDA approval of new drug applications for specific indications and up to $0.20 for achieving worldwide net sales of $200 million [8] Financial Support - Applied has issued a Promissory Note to Cycle, allowing for loans up to $8.5 million to support its working capital needs, with repayment obligations triggered if the transaction is terminated [5] Board Approval - The merger agreement was unanimously approved by the Applied Board of Directors after evaluating strategic alternatives, determining it to be in the best interest of the company and its stockholders [6]

WASHINGTON, Dec. 11, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 15, 2026.  A corporate presentation is scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time). The corporate presentation given at the J.P. Morgan Healthcare Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the ...

Adjourns 2025 Annual Meeting of StockholdersUrges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") was convened and adjourned without any business conducted due to lack of t ...

PresentationSean McClainFounder, CEO, President & Director Good morning, everyone. Thank you for joining our deep dive today into ABS-201. At Absci, our mission is to use generative AI to create better biologics for patients who don't have good enough options today. We talk a lot about our platform, our lab-in-the-loop, and our ability to create better biologics faster. But today isn't just about the platform in the abstract, today is about the results. ABS-201, which we believe could be a paradigm-changing ...

HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-bas ...